Achieve Life Sciences (ACHV) announced that additional analyses from its Phase 3 ORCA-3 study will be presented during an oral presentation at the 2025 American Thoracic Society International Conference in San Francisco, CA. The oral presentation will highlight the unique benefit of cytisinicline treatment in clinical trials in reducing nicotine cravings which led to reduced nicotine intake, even in individuals who did not achieve complete smoking cessation. These analyses reinforce the importance of the dual mechanism of action for cytisinicline as a highly selective partial agonist and antagonist at the nicotinic acetylcholine receptor.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences’ Optimistic Earnings Call Highlights
- Optimistic Buy Rating for Achieve Life Sciences Driven by Cytisinicline’s Regulatory Progress and Strategic Focus on Smoking and Vaping Cessation
- Achieve Life Sciences Reports Q1 2025 Results
- Positive Buy Rating for Achieve Life Sciences Amid Promising Cytisinicline Progress and Strategic Market Positioning
- Achieve Life Sciences reports Q1 EPS (37c), consensus (37c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue